Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.

被引：0
|
作者：
Han, Ting [1 ]
Lin, Xiaolin [1 ]
Zhuo, Meng [1 ]
Jiao, Feng [1 ]
Cui, Jiujie [1 ]
Qiu, Xiaoxia [1 ]
Xiao, Xiuying [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.3_suppl.353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：353 / 353
页数：1
相关论文
共 50 条
  • [31] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
    Wei, Wei
    Ban, Xiaohua
    Yang, Fan
    Huang, Yongwen
    Li, Jibin
    Qiu, Ya
    Cheng, Xiaqin
    Li, Jundong
    Zheng, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Efficacy and safety of camrelizumab combined with chemotherapy in the first-line treatment of advanced gastric cancer: a single-arm, phase II study
    Liu, Wenlou
    Wang, Hongmei
    Zhao, Yang
    Ge, Yan
    Tang, Juangjuang
    Cao, Menghan
    Matsas, Silvio
    Breadner, Daniel Adam
    Qin, Xiaobing
    Han, Zhengxiang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04)
  • [33] Surufatinib plus toripalimab and chemotherapy for second-line treatment of RAS/BRAF mutant (MT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-arm, phase II study (APHRODITE)
    Zhang, H.
    Liu, L.
    Zhu, X.
    Gao, Y.
    Tong, Z.
    Fu, Q.
    Bao, X.
    Dai, X.
    Zhao, P.
    Fang, W.
    Zheng, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S21 - S21
  • [34] Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
    Huh, Gunn
    Lee, Hee Seung
    Choi, Jin Ho
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [35] Pamiparib combined with surufatinib as a neoadjuvant therapy for advanced ovarian cancer patients in the entire population: Preliminary results of a prospective, exploratory, single-arm phase II clinical study
    Xia, B.
    Jiang, W.
    Chen, J.
    Chen, Y.
    Shan, W.
    Shen, W.
    Tian, Y.
    Chen, Y.
    Chen, X.
    Wu, W.
    Ma, Y.
    Wang, J.
    Qi, W.
    Wang, Z.
    Li, X.
    Huang, X.
    Lin, H.
    Hong, B.
    Zhou, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S520 - S520
  • [36] First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial
    Cytryn, Samuel L.
    Moy, Ryan H.
    Cowzer, Darren
    Shah, Ronak H.
    Chou, Joanne F.
    Joshi, Smita S.
    Ku, Geoffrey Y.
    Maron, Steven B.
    Desai, Avni
    Yang, Jessica
    Sugarman, Ryan
    Rao, Devika
    Goldberg, Zoe
    Charalambous, Carmelina
    Lapshina, Maria
    Antoine, Ariel
    Socolow, Fiona
    Trivedi, Nikhil
    Capanu, Marinela
    Gerdes, Hans
    Schattner, Mark A.
    Simmons, Marc
    Lacouture, Mario E.
    Paroder, Viktoriya
    Tang, Laura H.
    Shia, Jinru
    Ilson, David H.
    Solit, David B.
    Berger, Michael F.
    Janjigian, Yelena Y.
    LANCET ONCOLOGY, 2023, 24 (10): : 1073 - 1082
  • [37] Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: Updated results of a multi-center, single-arm, phase 2 trial
    Zhao, Wensi
    Li, Jun
    Li, Liping
    Huang, Junping
    Gong, Wei
    Yu, Xiongjie
    Le, Kefa
    He, Linli
    Han, Qi
    Wang, Songlin
    Tang, Ze
    Li, Wenbin
    Hua, Xianliang
    Chen, Yongshun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial
    How, Jeffrey A.
    Dang, Minghao
    Lee, Sanghoon
    Fellman, Bryan
    Westin, Shannon N.
    Sood, Anil K.
    Fleming, Nicole D.
    Shafer, Aaron
    Yuan, Ying
    Liu, Jinsong
    Zhao, Li
    Celestino, Joseph
    Hajek, Richard
    Morgan, Margaret B.
    Parra, Edwin R.
    Fernandez, Caddie D. Laberiano
    Arrechedera, Claudio A.
    Soto, Luisa Maren Solis
    Schmeler, Kathleen M.
    Nick, Alpa
    Lu, Karen H.
    Coleman, Robert
    Wang, Linghua
    Jazaeri, Amir A.
    MED, 2025, 6 (01):
  • [39] Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
    Wang, Huaying
    Tian, Wenjuan
    Ren, Yulan
    Jing, Chuyu
    Shan, Boer
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Single agent olaparib in advanced oesophago-gastric cancer: Primary results from the SOlar clinical phase II single arm trial.
    Cartwright, Elizabeth
    Tran, Amina
    Saffery, Claire
    Zhitkov, Oleg
    Leamon, Becky
    Rana, Isma
    Johnston, Ed
    Hewish, Madeleine
    Sita-Lumsden, Ailsa
    Fribbens, Charlotte Victoria
    Rao, Sheela
    Chau, Ian
    Cunningham, David
    Starling, Naureen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 427 - 427
12345